Kawali Ankush, Khanum Aayesha, Mishra Sai B, Sanjay Srinivasan, Mahendradas Padmamalini
Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bangalore, Karnataka, India.
Department of Retina, Narayana Nethralaya, Bangalore, Karnataka, India.
Indian J Ophthalmol. 2024 Dec 1;72(12):1694-1703. doi: 10.4103/IJO.IJO_689_24. Epub 2024 Aug 14.
Acute retinal necrosis (ARN) is a sight-threatening ophthalmic emergency that requires aggressive treatment to prevent irreversible vision loss. However, primary treatment failure (PTF), where the initial antiviral therapy is ineffective, is a common challenge in ARN management. This comprehensive review examines PTF in ARN, drawing insights from a systematic literature search spanning 1997 to 2022, which identified 35 relevant cases from 23 reports. The analysis focuses on drug resistance patterns, alternative antiviral agents, combination therapies, and emerging treatments. Potential causes of drug resistance, including host factors, viral mutations, and drug-related considerations, are elucidated. Alternative agents such as foscarnet, cidofovir, and brivudine, as well as combination approaches involving systemic and intravitreal administration, high-dose therapy, judicious use of steroids, and potential treatment-related complications, are discussed. The review also highlights emerging therapies, including vaccines, monoclonal antibodies, and natural compounds, offering insights into future directions for addressing this challenging condition.
急性视网膜坏死(ARN)是一种威胁视力的眼科急症,需要积极治疗以防止不可逆转的视力丧失。然而,初始抗病毒治疗无效的原发性治疗失败(PTF)是ARN治疗中的一个常见挑战。本综述全面研究了ARN中的PTF,通过对1997年至2022年的系统文献检索获取见解,该检索从23份报告中确定了35例相关病例。分析重点在于耐药模式、替代抗病毒药物、联合疗法和新兴治疗方法。阐明了耐药的潜在原因,包括宿主因素、病毒突变和与药物相关的因素。讨论了诸如膦甲酸钠、西多福韦和溴夫定等替代药物,以及涉及全身和玻璃体内给药、高剂量治疗、谨慎使用类固醇和潜在治疗相关并发症的联合方法。该综述还强调了新兴疗法,包括疫苗、单克隆抗体和天然化合物,为应对这一具有挑战性的病症提供了未来方向的见解。